Nektar Therapeutics Payments to Acquire Debt Securities, Available-for-sale
Nektar Therapeutics (NKTR) reported Payments to Acquire Debt Securities, Available-for-sale of $987.71 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-14
- Nektar Therapeutics payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $535.45M, a 2729.95% increase year-over-year.
- Nektar Therapeutics payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $452.25M, a 1714.02% increase year-over-year.
- Nektar Therapeutics payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $91.60M, a 31.18% increase year-over-year.
- Nektar Therapeutics payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $149.56M, a 713.79% increase year-over-year.
- Nektar Therapeutics payments to acquire debt securities, available-for-sale for fiscal 2025 was $285.01M, a 8.90% increase from fiscal 2024.
- Nektar Therapeutics payments to acquire debt securities, available-for-sale for fiscal 2024 was $261.71M, a 48.85% decline from fiscal 2023.
- Nektar Therapeutics payments to acquire debt securities, available-for-sale for fiscal 2023 was $511.70M, a 9.36% increase from fiscal 2022.
- Nektar Therapeutics payments to acquire debt securities, available-for-sale for fiscal 2022 was $467.91M, a 51.29% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $535.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $987.71M 10-Q · filed 2026-08-14 | $1.08B derived: sum of 3 quarters · filed 2026-08-14 | $1.23B derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $452.25M 10-Q · filed 2026-05-08 | $543.86M derived: sum of 2 quarters · filed 2026-05-08 | $693.41M derived: sum of 3 quarters · filed 2026-05-08 | $712.33M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $91.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $241.16M derived: sum of 2 quarters · filed 2026-03-13 | $260.08M derived: sum of 3 quarters · filed 2026-08-14 | $285.01M 10-K · filed 2026-03-13 |
| 2025-09-30 | $149.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $168.48M derived: sum of 2 quarters · filed 2026-08-14 | $193.41M 10-Q · filed 2025-11-07 | $263.24M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $18.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $43.85M 10-Q · filed 2026-08-14 | $113.68M derived: sum of 3 quarters · filed 2026-08-14 | $132.06M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $24.93M 10-Q · filed 2026-05-08 | $94.76M derived: sum of 2 quarters · filed 2026-05-08 | $113.14M derived: sum of 3 quarters · filed 2026-05-08 | $181.58M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $69.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $88.20M derived: sum of 2 quarters · filed 2026-03-13 | $156.65M derived: sum of 3 quarters · filed 2026-03-13 | $261.71M 10-K · filed 2026-03-13 |
| 2024-09-30 | $18.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $86.82M derived: sum of 2 quarters · filed 2025-11-07 | $191.88M 10-Q · filed 2025-11-07 | $330.76M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $68.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $173.50M 10-Q · filed 2025-08-08 | $312.38M derived: sum of 3 quarters · filed 2025-08-08 | $435.48M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $105.06M 10-Q · filed 2025-05-09 | $243.94M derived: sum of 2 quarters · filed 2025-05-09 | $367.03M derived: sum of 3 quarters · filed 2025-05-09 | $509.75M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $138.88M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $261.98M derived: sum of 2 quarters · filed 2025-03-14 | $404.69M derived: sum of 3 quarters · filed 2025-03-14 | $511.70M 10-K · filed 2025-03-14 |
| 2023-09-30 | $123.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $265.81M derived: sum of 2 quarters · filed 2024-11-08 | $372.82M 10-Q · filed 2024-11-08 | $545.30M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $142.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $249.72M 10-Q · filed 2024-08-09 | $422.20M derived: sum of 3 quarters · filed 2024-08-09 | $470.62M derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | $107.01M 10-Q · filed 2024-05-10 | $279.49M derived: sum of 2 quarters · filed 2024-05-10 | $327.91M derived: sum of 3 quarters · filed 2024-05-10 | $481.43M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $172.47M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $220.90M derived: sum of 2 quarters · filed 2024-03-05 | $374.42M derived: sum of 3 quarters · filed 2024-03-05 | $467.91M 10-K · filed 2024-03-05 |
| 2022-09-30 | $48.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $201.95M derived: sum of 2 quarters · filed 2023-11-08 | $295.44M 10-Q · filed 2023-11-08 | $440.08M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | $153.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $247.01M 10-Q · filed 2023-08-09 | $391.65M derived: sum of 3 quarters · filed 2024-03-05 | $679.82M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | $93.49M 10-Q · filed 2023-05-10 | $238.13M derived: sum of 2 quarters · filed 2024-03-05 | $526.29M derived: sum of 3 quarters · filed 2024-03-05 | $758.87M derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | $144.64M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $432.80M derived: sum of 2 quarters · filed 2024-03-05 | $665.38M derived: sum of 3 quarters · filed 2024-03-05 | $960.69M 10-K · filed 2024-03-05 |
| 2021-09-30 | $288.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $520.74M derived: sum of 2 quarters · filed 2022-11-04 | $816.05M 10-Q · filed 2022-11-04 | $1.01B derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $232.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $527.89M 10-Q · filed 2022-08-05 | $723.98M derived: sum of 3 quarters · filed 2023-02-28 | $971.79M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $295.31M 10-Q · filed 2022-05-06 | $491.40M derived: sum of 2 quarters · filed 2023-02-28 | $739.22M derived: sum of 3 quarters · filed 2023-02-28 | $1.04B derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $196.09M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $443.90M derived: sum of 2 quarters · filed 2023-02-28 | $746.47M derived: sum of 3 quarters · filed 2023-02-28 | $987.53M 10-K · filed 2023-02-28 |
| 2020-09-30 | $247.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $550.38M derived: sum of 2 quarters · filed 2021-11-05 | $791.45M 10-Q · filed 2021-11-05 | $1.14B derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $302.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $543.63M 10-Q · filed 2021-08-06 | $895.61M derived: sum of 3 quarters · filed 2022-03-01 | $1.32B derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $241.07M 10-Q · filed 2021-05-07 | $593.05M derived: sum of 2 quarters · filed 2022-03-01 | $1.02B derived: sum of 3 quarters · filed 2022-03-01 | $1.25B derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $351.98M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $777.16M derived: sum of 2 quarters · filed 2022-03-01 | $1.01B derived: sum of 3 quarters · filed 2022-03-01 | $1.38B 10-K · filed 2022-03-01 |
| 2019-09-30 | $425.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $660.14M derived: sum of 2 quarters · filed 2020-11-06 | $1.03B 10-Q · filed 2020-11-06 | $1.36B derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $234.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $603.70M 10-Q · filed 2020-08-07 | $930.77M derived: sum of 3 quarters · filed 2021-02-26 | $1.89B derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $368.74M 10-Q · filed 2020-05-08 | $695.81M derived: sum of 2 quarters · filed 2021-02-26 | $1.65B derived: sum of 3 quarters · filed 2021-02-26 | |
| 2018-12-31 | $327.07M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $1.28B derived: sum of 2 quarters · filed 2021-02-26 | $2.27B 10-K · filed 2021-02-26 | |
| 2018-09-30 | $954.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $1.94B 10-Q · filed 2019-11-07 | ||
| 2018-06-30 | $989.85M 10-Q · filed 2019-08-09 | |||
| 2017-12-31 | $404.43M 10-K · filed 2020-02-28 | |||
| 2016-12-31 | $334.66M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |